Neurotoxicity of amyloid β-protein: Synaptic and network dysfunction

Cold Spring Harbor Perspectives in Medicine

Volumn 2, Issue 7, 2012, Pages

  Mucke, Lennart ^a   Selkoe, Dennis J ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Brigham and Women's Hospital Center for Neurologic Diseases   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA AMINO 3 HYDROXY 5 METHYL 4 ISOXAZOLEPROPIONIC ACID; ALPHA SYNUCLEIN; AMYLOID BETA PROTEIN; BETA SECRETASE 1; EPHRIN RECEPTOR B2; HUNTINGTIN; METABOTROPIC RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE P38; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NICOTINIC RECEPTOR ALPHA4BETA2; OLIGOMER;

AMYLOID PLAQUE; ARTICLE; COGNITIVE DEFECT; DENDRITIC SPINE; DESENSITIZATION; DOWN SYNDROME; ELECTROSTIMULATION; HUMAN; IMMUNOPRECIPITATION; LONG TERM DEPRESSION; LONG TERM POTENTIATION; NERVE CELL PLASTICITY; NERVE DEGENERATION; NEUROTOXICITY; SENILE PLAQUE; SLEEP WAKING CYCLE; SYNAPTIC TRANSMISSION; WESTERN BLOTTING; ALZHEIMER DISEASE; ANIMAL; CHEMISTRY; EXTRACELLULAR SPACE; METABOLISM; NERVE CELL; NERVE CELL NETWORK; REVIEW; SYNAPSE;

ANIMALIA;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; EXTRACELLULAR SPACE; HUMANS; NERVE NET; NEURONS; SYNAPSES; SYNAPTIC TRANSMISSION;

EID: 84880759156     PISSN: None     EISSN: 21571422     Source Type: Journal    
DOI: 10.1101/cshperspect.a006338     Document Type: Article

References (109)

1. Abramov E, Dolev I, Fogel H, Ciccotosto GD, Ruff E, Slutsky I. 2009. Amyloid-β as a positive endogenous regulator of release probability at hippocampal synapses. Nat Neurosci 12: 1567-1576.
2. Almeida CG, Takahashi RH, Gouras GK. 2006. β-Amyloid accumulation impairs multivesicular body sorting by inhibiting the ubiquitin-proteasome system. J Neurosci 26: 4277-4288.
3. Balducci C, Beeg M, Stravalaci M, Bastone A, Sclip A, Biasini E, Tapella L, Colombo L, Manzoni C, Borsello T, et al. 2010. Synthetic amyloid-{β} oligomers impair long-term memory independently of cellular prion protein. Proc Natl Acad Sci 107: 2295-2300.
4. Barry AE, Klyubin I, McDonald JM, Mably AJ, Farrell MA, Scott M, Walsh DM, Rowan MJ. 2011. Alzheimer's disease brain-derived amyloid-mediated inhibition of LTP in vivo is prevented by immunotargeting cellular prion protein. J Neurosci 31: 7259-7263.
5. Bitan G, Lomakin A, Teplow DB. 2001. Amyloid β-protein oligomerization: Prenucleation interactions revealed by photo-induced cross-linking of unmodified proteins. J Biol Chem 276: 35176-35184.
6. Busche MA, Eichhoff G, Adelsberger H, Abramowski D, Wiederhold KH, HaassC, Staufenbiel M, Konnerth A, Garaschuk O. 2008. Clusters of hyperactive neurons near amyloid plaques in a mouse model of Alzheimer's disease. Science 321: 1686-1689.
7. Buttini M, Yu G-Q, Shockley K, Huang Y, Jones B, Masliah E, Mallory M, Yeo T, Longo FM, Mucke L. 2002. Modulation of Alzheimer-like synaptic and cholinergic deficits in transgenic mice by human apolipoprotein E depends on isoform, aging, and overexpression of amyloid β peptides but not on plaque formation. J Neurosci 22: 10539-10548.
8. Calella AM, Farinelli M, Nuvolone M, Mirante O, Moos R, Falsig J, Mansuy IM, Aguzzi A. 2010. Prion protein and Aβ-related synaptic toxicity impairment. EMBO Mol Med 2: 306-314.
9. Chen JX, Yan SD. 2007. Amyloid-β-induced mitochondrial dysfunction. J Alzheimer's Dis 12: 177-184.
10. Cirrito JR, Yamada KA, Finn MB, Sloviter RS, Bales KR, May PC, Schoepp DD, Paul SM, Mennerick S, Holtzman DM. 2005. Synaptic activity regulates interstitial fluid amyloid-β levels in vivo. Neuron 48: 913-922.
11. Cisse M, Halabisky B, Harris JA, Devidze N, Dubal D, Lotz G, Kim DH, Hamto T, Ho K, Yu G-Q, et al. 2011a. Reversing EphB2 depletion rescues cognitive functions in Alzheimer model. Nature 469: 47-52.
12. Cisse M, Sanchez PE, Kim DH, Yu G-Q, Mucke L. 2011b. Ablation of cellular prion protein does not ameliorate abnormal neural network activity and cognitive dysfunction in the J20 line of human amyloid precursor protein transgenic mice. J Neurosci 31: 10427-10431.
13. Cleary JP, Walsh DM, Hofmeister JJ, Shankar GM, Kuskowski MA, Selkoe DJ, Ashe KH. 2005. Natural oligomers of the amyloid-β protein specifically disrupt cognitive function. Nat Neurosci 8: 79-84.
14. DeKosky ST, Scheff SW. 1990. Synapse loss in frontal cortex biopsies in Alzheimer's disease: Correlation with cognitive severity. Ann Neurol 27: 457-464.
15. Demuro A, Mina E, Kayed R, Milton SC, Parker I, Glabe CG. 2005. Calcium dysregulation and membrane disruption as a ubiquitous neurotoxic mechanism of soluble amyloid oligomers. J Biol Chem 280: 17294-17300.
16. Dineley KT, Bell KA, Bui D, Sweatt JD. 2002. β-Amyloid peptide activates α7 nicotinic acetylcholine receptors expressed in Xenopus oocytes. J Biol Chem 277: 25056-25061.
17. Gimbel DA, Nygaard HB, Coffey EE, Gunther EC, Lauren J, Gimbel ZA, Strittmatter SM. 2010. Memory impairment in transgenic Alzheimer mice requires cellular prion protein. J Neurosci 30: 6367-6374.
18. Golde TE, Schneider LS, Koo EH. 2011. Anti-aβ therapeutics in Alzheimer's disease: The need for a paradigm shift. Neuron 69: 203-213.
19. Gong Y, Chang L, Viola KL, Lacor PN, Lambert MP, Finch CE, Krafft GA, KleinWL. 2003. Alzheimer's disease-affected brain: Presence of oligomeric Aβ ligands (ADDLs) suggests a molecular basis for reversible memory loss. Proc Natl Acad Sci 100: 10417-10422.
20. Gouras GK, Almeida CG, Takahashi RH. 2005. Intraneuronal Aβ accumulation and origin of plaques in Alzheimer's disease. Neurobiol Aging 26: 1235-1244.
21. Haass C, Schlossmacher M, Hung AY, Vigo-Pelfrey C, Mellon A, OstaszewskiB, Lieberburg I, Koo EH, Schenk D, Teplow D, et al. 1992. Amyloid β-peptide is produced by cultured cells during normal metabolism. Nature 359: 322-325.
22. Haass C, Kaether C, Sisodia S, Thinakaran G. 2011. Trafficking and proteolytic processing of APP. Cold Spring Harb Perspect Med doi: 10. 1101/cshperspect. a006270.
23. Hardy JA, Higgins GA. 1992. Alzheimer's disease: The amyloid cascade hypothesis. Science 256: 184-185.
24. Harper JD, Wong SS, Lieber CM, Lansbury PT Jr. 1997. Observation of metastable Ab amyloid protofibrils by atomic force microscopy. Chem Biol 4: 119-125.
25. Harris JA, Devidze N, Verret L, Ho K, Hamto T, Lo I, Yu G-Q, Palop JJ, MasliahE, Mucke L. 2010. Transsynaptic progression of amyloid-β-induced neuronal dysfunction within the entorhinal-hippocampal network. Neuron 68: 428-441.
26. Hartley D, Walsh DM, Ye CP, Diehl T, Vasquez S, Vassilev PM, Teplow DB, Selkoe DJ. 1999. Protofibrillar intermediates of amyloid β-protein induce acute electrophysiological changes and progressive neurotoxicity in cortical neurons. J Neurosci 19: 8876-8884.
27. Holcomb LA, Gordon MN, Jantzen P, Hsiao K, Duff K, Morgan D. 1999. Behavioral changes in transgenic mice expressing both amyloid precursor protein and presenilin-1 mutations: Lack of association with amyloid deposits. Behav Genet 29: 177-185.
28. Hoover BR, Reed MN, Su J, Penrod RD, Kotilinek LA, Grant MK, Pitstick R, Carlson GA, Lanier LM, Yuan LL, et al. 2010. Tau mislocalization to dendritic spines mediates synaptic dysfunction independently of neurodegeneration. Neuron 68: 1067-1081.
29. Hsia AY, Masliah E, McConlogue L, Yu GQ, Tatsuno G, Hu K, Kholodenko D, Malenka RC, Nicoll RA, Mucke L. 1999. Plaque-independent disruption of neural circuits in Alzheimer's disease mouse models. Proc Natl Acad Sci 96: 3228-3233.
30. Hsieh H, Boehm J, Sato C, Iwatsubo T, Tomita T, Sisodia S, Malinow R. 2006. AMPAR removal underlies Aβ-induced synaptic depression and dendritic spine loss. Neuron 52: 831-843.
31. Hyman BT, West HL, Rebeck GW, Buldyrev SV, Mantegna RN, Ukleja M, HavlinS, Stanley HE. 1995. Quantitative analysis of senile plaques in Alzheimer's disease: Observation of log-normal size distribution and molecular epidemiology of differences associated with apolipoprotein E genotype and trisomy 21 (Down syndrome). Proc Natl Acad Sci 92: 3586-3590.
32. Ihara Y, Morishima-Kawashima M, Nixon R. 2011. The ubiquitin-proteasome system and the autophagiclysosomal system in Alzheimer disease. Cold Spring Harb Perspect Med doi: 10. 1101/cshperspect. a006361.
33. Ittner LM, Ke YD, Delerue F, Bi M, Gladbach A, van Eersel J, Wolfing H, ChiengBC, Christie MJ, Napier IA, et al. 2010. Dendritic function of tau mediates amyloid-β toxicity in Alzheimer's disease mouse models. Cell 142: 387-397.
34. Jin M, Shepardson N, Yang T, Walsh D, Selkoe D. 2011. Soluble amyloid β-protein dimers isolated from Alzheimer cortex directly induce Tau hyperphosphorylation and neuritic degeneration. Proc Natl Acad Sci 108: 5819-5824.
35. Kamenetz F, Tomita T, Hsieh H, Seabrook G, Borchelt D, Iwatsubo T, Sisodia S, Malinow R. 2003. APP processing and synaptic function. Neuron 37: 925-937.
36. Kang JE, Lim MM, Bateman RJ, Lee JJ, Smyth LP, Cirrito JR, Fujiki N, Nishino S, Holtzman DM. 2009. Amyloid-β dynamics are regulated by orexin and the sleep-wake cycle. Science 326: 1005-1007.
37. Kawarabayashi T, Younkin LH, Saido TC, Shoji M, Ashe KH, Younkin SG. 2001. Age-dependent changes in brain, CSF, and plasma amyloid (β) protein in the Tg2576 transgenic mouse model of Alzheimer's disease. J Neurosci 21: 372-381.
38. Kayed R, Head E, Thompson JL, McIntire TM, Milton SC, Cotman CW, Glabe CG. 2003. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 300: 486-489.
39. Kessels HW, Malinow R. 2009. Synaptic AMPA receptor plasticity and behavior. Neuron 61: 340-350.
40. Kim JH, Anwyl R, Suh YH, Djamgoz MB, Rowan MJ. 2001. Use-dependent effects of amyloidogenic fragments of (β)-amyloid precursor protein on synaptic plasticity in rat hippocampus in vivo. J Neurosci 21: 1327-1333.
41. Klyubin I, Walsh DM, Lemere CA, Cullen WK, Shankar GM, Betts V, Spooner ET, Jiang L, Anwyl R, Selkoe DJ, et al. 2005. Amyloid β protein immunotherapy neutralizes Aβ oligomers that disrupt synaptic plasticity in vivo. Nat Med 11: 556-561.
42. Koffie RM, Meyer-Luehmann M, Hashimoto T, Adams KW, Mielke ML, Garcia-Alloza M, Micheva KD, Smith SJ, Kim ML, Lee VM, et al. 2009. Oligomeric amyloid β associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques. Proc Natl Acad Sci 106: 4012-4017.
43. Kullmann DM, Lamsa KP. 2007. Long-term synaptic plasticity in hippocampal interneurons. Nat Rev Neurosci 8: 687-699.
44. Lacor PN, Buniel MC, Chang L, Fernandez SJ, Gong Y, Viola KL, Lambert MP, Velasco PT, Bigio EH, Finch CE, et al. 2004. Synaptic targeting by Alzheimer's-related amyloid β oligomers. J Neurosci 24: 10191-10200.
45. Lacor PN, Buniel MC, Furlow PW, Clemente AS, Velasco PT, Wood M, Viola KL, Klein WL. 2007. Aβ oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer's disease. J Neurosci 27: 796-807.
46. Laird FM, Cai H, Savonenko AV, Farah MH, He K, Melnikova T, Wen H, ChiangHC, Xu G, Koliatsos VE, et al. 2005. BACE1, a major determinant of selective vulnerability of the brain to amyloid-β amyloidogenesis, is essential for cognitive, emotional, and synaptic functions. J Neurosci 25: 11693-11709.
47. 1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci 95: 6448-6453.
48. Lauren J, Gimbel DA, Nygaard HB, Gilbert JW, Strittmatter SM. 2009. Cellular prion protein mediates impairment of synaptic plasticity by amyloid-β oligomers. Nature 457: 1128-1132.
49. Lesne S, Koh MT, Kotilinek L, Kayed R, Glabe CG, Yang A, Gallagher M, AsheKH. 2006. A specific amyloid-β protein assembly in the brain impairs memory. Nature 440: 352-357.
50. Lewin R. 1980. Is your brain really necessary? Science 210: 1232-1234.
51. Li S, Hong S, Shepardson NE, Walsh DM, Shankar GM, Selkoe D. 2009. Soluble oligomers of amyloid β protein facilitate hippocampal long-term depression by disrupting neuronal glutamate uptake. Neuron 62: 788-801.
52. Li S, Jin M, Koeglsperger T, Shepardson NE, Shankar GM, Selkoe DJ. 2011. Soluble Aβ oligomers inhibit long-term potentiation through a mechanism involving excessive activation of extrasynaptic NR2B-containing NMDA receptors. J Neurosci 31: 6627-6638.
53. Lin H, Bhatia R, Lal R. 2001. Amyloid β protein forms ion channels: Implications for Alzheimer's disease pathophysiology. FASEB J 15: 2433-2444.
54. Liu L, Wong TP, Pozza MF, Lingenhoehl K, Wang Y, Sheng M, Auberson YP, Wang YT. 2004. Role of NMDA receptor subtypes in governing the direction of hippocampal synaptic plasticity. Science 304: 1021-1024.
55. Mahley RW, Weisgraber KH, Huang Y. 2006. Apolipoprotein E4: A causative factor and therapeutic target in neuropathology, including Alzheimer's disease. Proc Natl Acad Sci 103: 5644-5651.
56. Martins IC, Kuperstein I, Wilkinson H, Maes E, Vanbrabant M, Jonckheere W, Van Gelder P, Hartmann D, D'Hooge R, De Strooper B, et al. 2008. Lipids revert inert Aβ amyloid fibrils to neurotoxic protofibrils that affect learning in mice. Embo J 27: 224-233.
57. McLaurin J, Kierstead ME, Brown ME, Hawkes CA, Lambermon MH, Phinney AL, Darabie AA, Cousins JE, French JE, Lan MF, et al. 2006. Cyclohexanehexol inhibitors of Aβ aggregation prevent and reverse Alzheimer phenotype in a mouse model. Nat Med 12: 801-808.
58. McLean CA, Cherny RA, Fraser FW, Fuller SJ, Smith MJ, Beyreuther K, Bush AI, Masters CL. 1999. Soluble pool of Aβ amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann Neurol 46: 860-866.
59. Meilandt WJ, Yu G-Q, Chin J, Roberson ED, Palop JJ, Wu T, Scearce-Levie K, Mucke L. 2008. Enkephalin elevations contribute to neuronal and behavioral impairments in a transgenic mouse model of Alzheimer's disease. J Neurosci 28: 5007-5017.
60. Minkeviciene R, Rheims S, Dobszay MB, Zilberter M, Hartikainen J, Fulop L, Penke B, Zilberter Y, Harkany T, Pitkanen A, et al. 2009. Amyloid β-induced neuronal hyperexcitability triggers progressive epilepsy. J Neurosci 29: 3453-3462.
61. Morris M, Maeda S, Vossel K, Mucke L. 2011. The many faces of tau. Neuron 70: 410-426.
62. Mucke L, Masliah E, Yu GQ, Mallory M, Rockenstein EM, Tatsuno G, Hu K, Kholodenko D, Johnson-Wood K, McConlogue L. 2000. High-level neuronal expression of aβ 1-42 in wild-type human amyloid protein precursor transgenic mice: Synaptotoxicity without plaque formation. J Neurosci 20: 4050-4058.
63. Palop JJ, Mucke L. 2009. Epilepsy and cognitive impairments in Alzheimer disease. Arch Neurol 66: 435-440.
64. Palop JJ, Mucke L. 2010. Amyloid-β-induced neuronal dysfunction in Alzheimer's disease: From synapses toward neural networks. Nat Neurosci 13: 812-818.
65. Palop JJ, Jones B, Kekonius L, Chin J, Yu G-Q, Raber J, Masliah E, Mucke L. 2003. Neuronal depletion of calcium-dependent proteins in the dentate gyrus is tightly linked to Alzheimer's disease-related cognitive deficits. Proc Natl Acad Sci 100: 9572-9577.
66. Palop JJ, Chin J, Bien-Ly N, Massaro C, Yeung BZ, Yu GQ, Mucke L. 2005. Vulnerability of dentate granule cells to disruption of arc expression in human amyloid precursor protein transgenic mice. J Neurosci 25: 9686-9693.
67. Palop JJ, Chin J, Mucke L. 2006. A network dysfunction perspective on neurodegenerative diseases. Nature 443: 768-773.
68. Palop JJ, Chin J, Roberson ED, Wang J, Thwin MT, Bien-Ly N, Yoo J, Ho KO, YuG-Q, Kreitzer A, et al. 2007. Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer's disease. Neuron 55: 697-711.
69. Podlisny MB, Ostaszewski BL, Squazzo SL, Koo EH, Rydel RE, Teplow DB, Selkoe DJ. 1995a. Aggregation of secreted amyloid β-protein into SDS-stable oligomers in cell culture. J Biol Chem 270: 9564-9570.
70. Puzzo D, Privitera L, Leznik E, Fa M, Staniszewski A, Palmeri A, Arancio O. 2008. Picomolar amyloid-β positively modulates synaptic plasticity and memory in hippocampus. J Neurosci 28: 14537-14545.
71. Raber J, Wong D, Yu G-Q, Buttini M, Mahley RW, Pitas RE, Mucke L. 2000. Alzheimer's disease: Apolipoprotein E and cognitive performance. Nature 404: 352-354.
72. Roberson ED, Halabisky B, Yoo JW, Yao J, Chin J, Yan F, Wu T, Hamto P, Devidze N, Yu G-Q, et al. 2011. Amyloid-β/Fyn-induced synaptic, network, and cognitive impairments depend on Tau levels in multiple mouse models of Alzheimer's disease. J Neurosci 31: 700-711.
73. Roberson ED, Scearce-Levie K, Palop JJ, Yan F, Cheng IH, Wu T, Gerstein H, YuG-Q, Mucke L. 2007. Reducing endogenous tau ameliorates Amyloid beta-induced deficits in an Alzheimer's disease mouse model. Science 316: 750-754.
74. Roher AE, Chaney MO, Kuo Y-M, Webster SD, Stine WB, Haverkamp LJ, WoodsAS, Cotter RJ, Tuohy JM, Krafft GA, et al. 1996. Morphology and toxicity of Aβ-(1-42) dimer derived from neuritic and vascular amyloid deposits of Alzheimer's disease. J Biol Chem 271: 20631-20635.
75. Sanchez-Mejia RO, Newman JW, Toh S, G-Q Y, Zhou Y, Halabisky B, Cisse M, Scearce-Levie K, Cheng IH, Gan L, et al. 2008. Phospholipase A2 reduction ameliorates cognitve deficits in mouse model of Alzheimer's disease. Nat Neurosci 11: 1311-1318.
76. SantaCruz K, Lewis J, Spires T, Paulson J, Kotilinek L, Ingelsson M, GuimaraesA, DeTure M, Ramsden M, McGowan E, et al. 2005. Tau suppression in a neurodegenerative mouse model improves memory function. Science 309: 476-481.
77. Saura CA, Choi SY, Beglopoulos V, Malkani S, Zhang D, Shankaranarayana RaoBS, Chattarji S, Kelleher RJ, Kandel ER, Duff K, et al. 2004. Loss of presenilin function causes impairments of memory and synaptic plasticity followed by age-dependent neurodegeneration. Neuron 42: 23-36.
78. Schenk D, Basi GS, Pangalos MN. 2011. Treatment strategies targeting amyloid β-protein. Cold Spring Harb Perspect Med doi: 10. 1101/cshperspect. a006387.
79. Seabrook GR, Smith DW, Bowery BJ, Easter A, Reynolds T, Fitzjohn SM, MortonRA, Zheng H, Dawson GR, Sirinathsinghji DJS, et al. 1999. Mechanisms contributing to the deficits in hippocampal synaptic plasticity in mice lacking amyloid precursor protein. Neuropharmacology 38: 349-359.
80. Selkoe DJ. 1991. The molecular pathology of Alzheimer's disease. Neuron 6: 487-498.
81. Selkoe DJ. 2002. Alzheimer's disease is a synaptic failure. Science 298: 789-791.
82. Selkoe DJ. 2011. Resolving controversies on the path to Alzheimer's therapeutics. Nat Med 17: 1060-1065.
83. Serrano-Pozo A, Frosch MP, Masliah E, Hyman BT. 2011. Neuropathological alterations in Alzheimer disease. Cold Spring Harb Pespect Med doi: 10. 1101/cshperspect. a006189.
84. Serrano-Pozo A, William CM, Ferrer I, Uro-Coste E, Delisle MB, Maurage CA, Hock C, Nitsch RM, Masliah E, Growdon JH, et al. 2010. Beneficial effect of human anti-amyloid-β active immunization on neurite morphology and tau pathology. Brain 133: 1312-1327.
85. Shankar GM, Bloodgood BL, Townsend M, Walsh DM, Selkoe DJ, Sabatini BL. 2007. Natural oligomers of the Alzheimer amyloid-β protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. J Neurosci 27: 2866-2875.
86. Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepardson NE, Smith I, BrettFM, Farrell MA, Rowan MJ, Lemere CA, et al. 2008. Amyloid-β protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med 14: 837-842.
87. Shankar GM, Leissring MA, Adame A, Sun X, Spooner E, Masliah E, Selkoe DJ, Lemere CA, Walsh DM. 2009. Biochemical and immunohistochemical analysis of an Alzheimer's disease mouse model reveals the presence of multiple cerebral Aβ assembly forms throughout life. Neurobiol Dis 36: 293-302.
88. Shipton OA, Leitz JR, Dworzak J, Acton CE, Tunbridge EM, Denk F, Dawson HN, Vitek MP, Wade-Martins R, Paulsen O, et al. 2011. Tau protein is required for amyloid {β}-induced impairment of hippocampal long-term potentiation. J Neurosci 31: 1688-1692.
89. Shoji M, Golde TE, Ghiso J, Cheung TT, Estus S, Shaffer LM, Cai X, McKay DM, Tintner R, Frangione B, et al. 1992. Production of the Alzheimer amyloid β protein by normal proteolytic processing. Science 258: 126-129.
90. Simakova O, Arispe NJ. 2007. The cell-selective neurotoxicity of the Alzheimer's Aβ peptide is determined by surface phosphatidylserine and cytosolic ATP levels. Membrane binding is required for Aβ toxicity. J Neurosci 27: 13719-13729.
91. Snyder EM, Nong Y, Almeida CG, Paul S, Moran T, Choi EY, Nairn AC, SalterMW, Lombroso PJ, Gouras GK, et al. 2005a. Regulation of NMDA receptor trafficking by amyloid-β. Nat Neurosci 8: 1051-1058.
92. Spires-Jones TL, Meyer-Luehmann M, Osetek JD, Jones PB, Stern EA, BacskaiBJ, Hyman BT. 2007. Impaired spine stability underlies plaque-related spine loss in an Alzheimer's disease mouse model. Am J Pathol 171: 1304-1311.
93. Sun B, Halabisky B, Zhou Y, Palop JJ, Yu GQ, Mucke L, Gan L. 2009. Imbalance between GABAergic and glutamatergic transmissions impairs adult neurogenesis in an animal model of Alzheimer's disease. Cell Stem Cell 5: 624-633.
94. Supnet C, Bezprozvanny I. 2010. The dysregulation of intracellular calcium in Alzheimer disease. Cell Calcium 47: 183-189.
95. Tackenberg C, Brandt R. 2009. Divergent pathways mediate spine alterations and cell death induced by amyloid-β, wild-type tau, and R406W tau. J Neurosci 29: 14439-14450.
96. Takahashi RH, Milner TA, Li F, Nam EE, Edgar MA, Yamaguchi H, Beal MF, Xu H, Greengard P, Gouras GK. 2002. Intraneuronal Alzheimer aβ42 accumulates in multivesicular bodies and is associated with synaptic pathology. Am J Pathol 161: 1869-1879.
97. Takahashi RH, Almeida CG, Kearney PF, Yu F, Lin MT, Milner TA, Gouras GK. 2004. Oligomerization of Alzheimer's β-amyloid within processes and synapses of cultured neurons and brain. J Neurosci 24: 3592-3599.
98. Terry RD, Masliah E, Salmon DP, Butters N, DeTeresa R, Hill R, Hansen LA, Katzman R. 1991. Physical basis of cognitive alterations in Alzheimer's disease: Synapse loss is the major correlate of cognitive impairment. Ann Neurol 30: 572-580.
99. Verdier Y, Zarándi M, Penke B. 2004. Amyloid β-peptide interactions with neuronal and glial cell plasma membrane: Binding sites and implications for Alzheimer's disease. J Pept Sci 10: 229-248.
100. Vogt DL, Thomas D, Galvan V, Bredesen DE, Lamb BT, Pimplikar SW. 2009. Abnormal neuronal networks and seizure susceptibility in mice overexpressing the APP intracellular domain. Neurobiol Aging 32: 1725-1729.
101. Walsh DM, Lomakin A, Benedek GB, Maggio JE, Condron MM, Teplow DB. 1997. Amyloid b-protein fibrillogenesis: Detection of a protofibrillar intermediate. J Biol Chem 272: 22364-22374.
102. Walsh DM, Tseng BP, Rydel RE, Podlisny MB, Selkoe DJ. 2000. Detection of intracellular oligomers of amyloid β-protein in cells derived from human brain. Biochemistry 39: 10831-10839.
103. Walsh D, Klyubin I, Fadeeva J, William K. Cullen W, Anwyl R, Wolfe M, Rowan M, Selkoe D. 2002. Naturally secreted oligomers of the Alzheimer amyloid β-protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416: 535-539.
104. Wang Q, Walsh DM, Rowan MJ, Selkoe DJ, Anwyl R. 2004. Block of long-term potentiation by naturally secreted and synthetic amyloid β-peptide in hippocampal slices is mediated via activation of the kinases c-Jun N-terminal kinase, cyclin-dependent kinase 5, and pp38 mitogen-activated protein kinase as well as metabotropic glutamate receptor type 5. J Neurosci 24: 3370-3378.
105. Wei W, Nguyen LN, Kessels HW, Hagiwara H, Sisodia S, Malinow R. 2010. Amyloid β from axons and dendrites reduces local spine number and plasticity. Nat Neurosci 13: 190-196.
106. Winton MJ, Lee EB, Sun E, Wong MM, Leight S, Zhang B, Trojanowski JQ, LeeVM. 2011. Intraneuronal APP, not free Aβ peptides in 3xTg-AD mice: Implications for tau versus Aβ-mediated Alzheimer neurodegeneration. J Neurosci 31: 7691-7699.
107. Yan SD, Roher A, Schmidt AM, Stern DM. 1999. Cellular cofactors for amyloid β-peptide-induced cell stress. Moving from cell culture to in vivo. Am J Pathol 155: 1403-1411.
108. Yang AJ, Chandswangbhuvana D, Margol L, Glabe CG. 1998. Loss of endosomal/lysosomal membrane impermeability is an early event in amyloid Aβ1-42 pathogenesis. J Neurosci Res 52: 691-698.
109. 2+ elevation, missorting of endogenous tau into dendrites, tau phosphorylation, and destruction of microtubules and spines. J Neurosci 30: 11938-11950.